141 related articles for article (PubMed ID: 38767772)
1. Tertiary lymphoid structures as a potential prognostic biomarker for combined hepatocellular-cholangiocarcinoma.
Gong W; Zhang S; Tian X; Chen W; He Y; Chen L; Ding T; Ren P; Shi L; Wu Q; Sun Y; Chen L; Guo H
Hepatol Int; 2024 May; ():. PubMed ID: 38767772
[TBL] [Abstract][Full Text] [Related]
2. Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma.
Shang T; Jiang T; Lu T; Wang H; Cui X; Pan Y; Xu M; Pei M; Ding Z; Feng X; Lin Y; Li X; Tan Y; Feng F; Dong H; Wang H; Dong L
Front Immunol; 2023; 14():1166497. PubMed ID: 37234171
[TBL] [Abstract][Full Text] [Related]
3. Spatial multimodal analysis revealed tertiary lymphoid structures as a risk stratification indicator in combined hepatocellular-cholangiocarcinoma.
Gan X; Dong W; You W; Ding D; Yang Y; Sun D; Li W; Ding W; Liang Y; Yang F; Zhou W; Dong H; Yuan S
Cancer Lett; 2024 Jan; 581():216513. PubMed ID: 38036041
[TBL] [Abstract][Full Text] [Related]
4. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
Ding GY; Ma JQ; Yun JP; Chen X; Ling Y; Zhang S; Shi JY; Chang YQ; Ji Y; Wang XY; Tan WM; Yuan KF; Yan B; Zhang XM; Liang F; Zhou J; Fan J; Zeng Y; Cai MY; Gao Q
J Hepatol; 2022 Mar; 76(3):608-618. PubMed ID: 34793865
[TBL] [Abstract][Full Text] [Related]
5. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
6. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
7. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
Calderaro J; Di Tommaso L; Maillé P; Beaufrère A; Nguyen CT; Heij L; Gnemmi V; Graham RP; Charlotte F; Chartier S; Wendum D; Vij M; Allende D; Diaz A; Fuster C; Rivière B; Herrero A; Augustin J; Evert K; Calvisi DF; Leow WQ; Leung HHW; Bednarsch J; Boleslawski E; Rela M; Chan AW; Forner A; Reig M; Pujals A; Favre L; Allaire M; Scatton O; Uguen A; Trépo E; Sanchez LO; Chatelain D; Remmelink M; Boulagnon-Rombi C; Bazille C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Kather JN; Gouw ASH; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Nault JC; Laurent A; Amaddeo G; Regnault H; de Martin E; Sempoux C; Navale P; Shinde J; Bacchuwar K; Westerhoff M; Lo RC; Sebbagh M; Guettier C; Lequoy M; Komuta M; Ziol M; Paradis V; Shen J; Caruso S
J Hepatol; 2022 Dec; 77(6):1586-1597. PubMed ID: 35987274
[TBL] [Abstract][Full Text] [Related]
8. Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy.
Nguyen CT; Caruso S; Maille P; Beaufrère A; Augustin J; Favre L; Pujals A; Boulagnon-Rombi C; Rhaiem R; Amaddeo G; di Tommaso L; Luciani A; Regnault H; Brustia R; Scatton O; Charlotte F; Brochériou I; Sommacale D; Soussan P; Leroy V; Laurent A; Le VK; Ta VT; Trinh HS; Tran TL; Gentien D; Rapinat A; Nault JC; Allaire M; Mulé S; Zucman-Rossi J; Pawlotsky JM; Tournigand C; Lafdil F; Paradis V; Calderaro J
Clin Cancer Res; 2022 Feb; 28(3):540-551. PubMed ID: 34785581
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma.
Deguchi S; Tanaka H; Suzuki S; Natsuki S; Mori T; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
BMC Cancer; 2022 Jun; 22(1):699. PubMed ID: 35751038
[TBL] [Abstract][Full Text] [Related]
10. Combined hepatocellular-cholangiocarcinoma and its mimickers: Diagnostic pitfalls in surgical pathology.
Laohawetwanit T; Lerttanatum N; Wanpiyarat N; Manasilp N; Chaiparnich S
Ann Diagn Pathol; 2021 Aug; 53():151770. PubMed ID: 34147845
[TBL] [Abstract][Full Text] [Related]
11. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?
Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C
Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649
[TBL] [Abstract][Full Text] [Related]
12. Integrative analysis of tertiary lymphoid structures and immune microenvironment in patients with esophageal carcinoma.
Yao Y; Xuan H; Wang J; Gong L; Gao W
Tumori; 2023 Oct; 109(5):466-480. PubMed ID: 37249074
[TBL] [Abstract][Full Text] [Related]
13. Infiltrating characteristics and prognostic value of tertiary lymphoid structures in resected gastric neuroendocrine neoplasm patients.
Cai D; Wang X; Yu H; Bai C; Mao Y; Liang M; Xia X; Liu S; Wang M; Lu X; Du J; Shen X; Guan W
Clin Transl Immunology; 2024; 13(2):e1489. PubMed ID: 38322490
[TBL] [Abstract][Full Text] [Related]
14. The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer.
Wang B; Liu J; Han Y; Deng Y; Li J; Jiang Y
Front Immunol; 2022; 13():868155. PubMed ID: 35664009
[TBL] [Abstract][Full Text] [Related]
15. Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors.
Wang Y; Zhu GQ; Zhou CW; Li N; Yang C; Zeng MS
Eur Radiol; 2022 Aug; 32(8):5166-5178. PubMed ID: 35316365
[TBL] [Abstract][Full Text] [Related]
16. Post-resection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma cannot be predicted by the 2019 World Health Organization classification.
Kim M; Hwang S; Ahn CS; Kim KH; Moon DB; Song GW; Jung DH; Hong SM
Asian J Surg; 2021 Nov; 44(11):1389-1395. PubMed ID: 33766528
[TBL] [Abstract][Full Text] [Related]
17. A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery.
Zhang F; Hu K; Tang B; Tian M; Lu S; Yuan J; Li M; Chen R; Ren Z; Shi Y; Yin X
J Gastrointest Surg; 2021 Apr; 25(4):971-982. PubMed ID: 32350718
[TBL] [Abstract][Full Text] [Related]
18. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
[TBL] [Abstract][Full Text] [Related]
19. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.
Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788
[TBL] [Abstract][Full Text] [Related]
20. Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors.
Dageforde LA; Vachharajani N; Tabrizian P; Agopian V; Halazun K; Maynard E; Croome K; Nagorney D; Hong JC; Lee D; Ferrone C; Baker E; Jarnagin W; Hemming A; Schnickel G; Kimura S; Busuttil R; Lindemann J; Florman S; Holzner ML; Srouji R; Najjar M; Yohanathan L; Cheng J; Amin H; Rickert CA; Yang JD; Kim J; Pasko J; Chapman WC; Majella Doyle MB
J Am Coll Surg; 2021 Apr; 232(4):361-371. PubMed ID: 33316425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
